495405-09-9 Usage
Uses
Used in Flavoring and Fragrance Industry:
Ethyl 3,4,5-trifluorobenzoate is used as a flavoring agent and fragrance ingredient for its fruity odor, enhancing the sensory experience of various products.
Used in Personal Care Products:
In the personal care industry, ethyl 3,4,5-trifluorobenzoate is used as an ingredient in products such as lotions, creams, and perfumes, contributing to their scent and overall appeal.
Used in Cosmetics:
Ethyl 3,4,5-trifluorobenzoate is incorporated into cosmetics for its pleasant aroma and as a component in the formulation of various cosmetic products.
Used in Pharmaceuticals:
ethyl 3,4,5-trifluorobenzoate is also used in the pharmaceutical industry, where it may be utilized in the development of medications or as a component in drug formulations.
Used in Organic Chemistry:
Ethyl 3,4,5-trifluorobenzoate serves as a building block in organic chemistry, aiding in the synthesis of other organic compounds for various applications.
It is important to handle ethyl 3,4,5-trifluorobenzoate with care, as it may cause irritation to the skin, eyes, and respiratory system, and could be harmful if ingested or inhaled.
Check Digit Verification of cas no
The CAS Registry Mumber 495405-09-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,9,5,4,0 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 495405-09:
(8*4)+(7*9)+(6*5)+(5*4)+(4*0)+(3*5)+(2*0)+(1*9)=169
169 % 10 = 9
So 495405-09-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H7F3O2/c1-2-14-9(13)5-3-6(10)8(12)7(11)4-5/h3-4H,2H2,1H3
495405-09-9Relevant academic research and scientific papers
Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold
Wu, Tianxiao,Qin, Qiaohua,Liu, Nian,Zhang, Chu,Lv, Ruicheng,Yin, Wenbo,Sun, Yin,Sun, Yixiang,Wang, Ruifeng,Zhao, Dongmei,Cheng, Maosheng
, (2022/01/13)
Tropomyosin receptor kinase (TRK) is an ideal target for treating cancers caused by the NTRK gene fusion. In this study, more than 60 2,4-diaminopyrimidine derivatives were prepared to understand the structure-activity relationship and confirm the rationality of the pharmacophore model reported previously. Among them, compound 19k was found to be a potent pan-TRK inhibitor that inhibits the proliferation of Km-12 cell lines. Additionally, compound 19k induced the apoptosis of Km-12 cells in a concentration-dependent manner. Western blot analysis revealed that compound 19k inhibited the phosphorylation of TRK to block downstream pathways. Compound 19k also possessed outstanding plasma stability and liver microsomal stability in vitro, with half-lives greater than 289.1 min and 145 min, respectively. Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17.4%. These results demonstrate that compound 19k could serve as a novel lead compound for overcoming NTRK-fusion cancers.
